Mitochondrial complex I deficiency in Parkinson's disease.

PubWeight™: 4.03‹?› | Rank: Top 1%

🔗 View Article (PMID 2154550)

Published in J Neurochem on March 01, 1990


A H Schapira1, J M Cooper, D Dexter, J B Clark, P Jenner, C D Marsden

Author Affiliations

1: Department of Neurological Science, Royal Free Hospital School of Medicine, London, England.

Articles citing this

(truncated to the top 100)

Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A (2003) 7.57

Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39

Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J (2012) 3.37

PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell (2009) 3.17

The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron (2015) 2.82

Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem (2009) 2.70

Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem (2008) 2.53

Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet (2011) 2.29

D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25

Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease. Annu Rev Pathol (2012) 2.20

A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10

Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia. Mol Cell Biol (1996) 1.76

Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev (2007) 1.72

The development of mitochondrial medicine. Proc Natl Acad Sci U S A (1994) 1.68

Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A (2005) 1.68

Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66

Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol (2005) 1.66

Complex I deficiency in Parkinson's disease frontal cortex. Brain Res (2007) 1.61

Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos Trans R Soc Lond B Biol Sci (2005) 1.55

Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr (2004) 1.53

Mitochondrial Morphology and Fundamental Parameters of the Mitochondrial Respiratory Chain Are Altered in Caenorhabditis elegans Strains Deficient in Mitochondrial Dynamics and Homeostasis Processes. PLoS One (2015) 1.53

Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol (2007) 1.52

Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.41

Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med (2008) 1.38

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA (2015) 1.37

Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35

Differential cytotoxicity of Mn(II) and Mn(III): special reference to mitochondrial [Fe-S] containing enzymes. Toxicol Appl Pharmacol (2001) 1.35

Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol (2013) 1.34

Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease. Cell Metab (2013) 1.32

PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One (2009) 1.30

Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.30

Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp Cell Res (2008) 1.29

Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol (1997) 1.28

Calcium signaling in neurodegeneration. Mol Neurodegener (2009) 1.27

N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav (2014) 1.27

Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. Proc Natl Acad Sci U S A (2011) 1.24

Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem (2011) 1.24

Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med (2008) 1.22

Nuclear transport, oxidative stress, and neurodegeneration. Int J Clin Exp Pathol (2011) 1.22

Mitochondria are the source of hydrogen peroxide for dynamic brain-cell signaling. J Neurosci (2009) 1.21

Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol (2013) 1.20

Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum Genet (2004) 1.19

Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res (2011) 1.17

Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res Rev (2014) 1.17

Nitric oxide inhibits mitochondrial NADH:ubiquinone reductase activity through peroxynitrite formation. Biochem J (2001) 1.16

Neuroprotective effects of near-infrared light in an in vivo model of mitochondrial optic neuropathy. J Neurosci (2008) 1.13

Nitric oxide in health and disease of the nervous system. Antioxid Redox Signal (2009) 1.13

Differential contribution of the mitochondrial respiratory chain complexes to reactive oxygen species production by redox cycling agents implicated in parkinsonism. Toxicol Sci (2009) 1.13

Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev (2013) 1.12

Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett (2008) 1.12

Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis (2009) 1.11

Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A (1997) 1.10

Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med (2008) 1.10

Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis (2011) 1.10

Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A (1994) 1.09

Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J (2006) 1.09

Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci (2011) 1.09

Oxidative stress and Parkinson's disease. Front Neuroanat (2015) 1.08

The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease. Parkinsons Dis (2011) 1.07

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med (2010) 1.07

Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease. J Bioenerg Biomembr (2009) 1.07

H2O2: a dynamic neuromodulator. Neuroscientist (2011) 1.07

TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP(+). Cell Calcium (2009) 1.07

Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson's disease. Transl Neurodegener (2012) 1.06

The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity. PLoS Genet (2012) 1.06

Exercise protects against MPTP-induced neurotoxicity in mice. Brain Res (2010) 1.05

AIF, reactive oxygen species, and neurodegeneration: a "complex" problem. Neurochem Int (2012) 1.02

Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease. Biomed Res Int (2014) 1.01

Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta (2009) 1.01

Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron (2015) 1.00

Persistent impairment of mitochondrial and tissue redox status during lithium-pilocarpine-induced epileptogenesis. J Neurochem (2010) 0.99

Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD. Parkinsons Dis (2011) 0.99

Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions. Biochim Biophys Acta (2011) 0.98

Genomic and biochemical approaches in the discovery of mechanisms for selective neuronal vulnerability to oxidative stress. BMC Neurosci (2009) 0.98

Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion (2009) 0.98

Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal (2011) 0.97

Analysis of the mitochondrial proteome in multiple sclerosis cortex. Biochim Biophys Acta (2011) 0.97

Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med (2015) 0.97

Loss of PINK1 increases the heart's vulnerability to ischemia-reperfusion injury. PLoS One (2013) 0.95

Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis (2007) 0.95

Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem (2008) 0.95

Extensive respiratory chain defects in inhibitory interneurones in patients with mitochondrial disease. Neuropathol Appl Neurobiol (2015) 0.95

The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med (2015) 0.94

Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease. Curr Bioact Compd (2008) 0.94

Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells. BMC Neurosci (2007) 0.94

DJ-1 knock-down impairs astrocyte mitochondrial function. Neuroscience (2011) 0.94

Vitiligo: a possible model of degenerative diseases. PLoS One (2013) 0.94

TRAP1 rescues PINK1 loss-of-function phenotypes. Hum Mol Genet (2013) 0.93

Catalytic antioxidants and neurodegeneration. Antioxid Redox Signal (2009) 0.93

Mitochondrial dynamics and mitophagy in Parkinson's disease: disordered cellular power plant becomes a big deal in a major movement disorder. Curr Opin Neurobiol (2011) 0.93

Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease. Front Aging Neurosci (2010) 0.93

Mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis (2011) 0.93

Protein expression in a Drosophila model of Parkinson's disease. J Proteome Res (2007) 0.93

A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila) (2008) 0.92

Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo. Neurobiol Dis (2008) 0.92

Complex I is rate-limiting for oxygen consumption in the nerve terminal. J Biol Chem (2009) 0.92

Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics (2014) 0.92

Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm (Vienna) (2009) 0.92

Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. Front Neuroanat (2010) 0.92

Multifactorial theory applied to the neurotoxicity of paraquat and paraquat-induced mechanisms of developing Parkinson's disease. Lab Invest (2016) 0.91

Articles by these authors

Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92

The Role of Peroxide in the Biological Effects of Irradiated Broth. J Bacteriol (1948) 6.42

Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72

Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69

The Production of Mutations in Staphylococcus aureus by Chemical Treatment of the Substrate. J Bacteriol (1947) 5.22

Servo action in the human thumb. J Physiol (1976) 4.93

Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77

Servo action in human voluntary movement. Nature (1972) 4.33

Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19

Method of determining oxygen concentrations in biological media, suitable for calibration of the oxygen electrode. Anal Biochem (1970) 4.11

Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain (1995) 3.71

Painful legs and moving toes. Brain (1971) 3.63

Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56

The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54

Writers' cramp-a focal dystonia. Brain (1982) 3.43

Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41

Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39

Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31

Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29

Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26

The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26

Corticobasal degeneration. Brain (1989) 3.20

Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16

Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97

The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81

Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77

Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76

Classification of dystonia. Adv Neurol (1998) 2.75

Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74

Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72

Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65

Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64

Manual motor performance in a deafferented man. Brain (1982) 2.63

The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60

Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58

The Rôle of Mutation and of Selection in the Frequency of Mutants Among Microörganisms Grown on Irradiated Substrate. Proc Natl Acad Sci U S A (1948) 2.55

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54

Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52

The pathophysiology of primary dystonia. Brain (1998) 2.51

Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50

A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50

Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45

Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44

Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40

A study of hereditary essential tremor. Brain (1994) 2.37

Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37

The metabolism of rat brain mitochondria. Preparation and characterization. J Biol Chem (1970) 2.37

'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36

Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36

Disturbance of sequential movements in patients with Parkinson's disease. Brain (1987) 2.30

Abnormalities in central motor pathway conduction in multiple sclerosis. Lancet (1984) 2.30

Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30

Isolated single motor units in human muscle and their rate of discharge during maximal voluntary effort. J Physiol (1971) 2.28

Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26

Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain (1977) 2.23

Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22

The problem of adult-onset idiopathic torsion dystonia and other isolated dyskinesias in adult life (including blepharospasm, oromandibular dystonia, dystonic writer's cramp, and torticollis, or axial dystonia). Adv Neurol (1976) 2.19

Delay in the execution of voluntary movement by electrical or magnetic brain stimulation in intact man. Evidence for the storage of motor programs in the brain. Brain (1989) 2.19

Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport (1996) 2.18

The sensory mechanism of servo action in human muscle. J Physiol (1977) 2.18

Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry (1976) 2.18

Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet (1997) 2.16

Epizootiology of neoplasms in bony fish of North America. Sci Total Environ (1990) 2.13

Hysteria--a neurologist's view. Psychol Med (1986) 2.12

Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10

Corticobasal degeneration. A clinical study of 36 cases. Brain (1994) 2.10

Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol (1996) 2.09

The metabolism of megestrol acetate (17-alpha-acetoxy-6-methylpregna-4, 6-diene-3, 20-dione) in the rabbit. Steroids (1965) 2.09

'Subcortical dementia': the neuropsychological evidence. Neuroscience (1988) 2.08

Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain (1995) 2.06

Ballistic flexion movements of the human thumb. J Physiol (1979) 2.06

Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. Mov Disord (2000) 2.06

Reciprocal inhibition between the muscles of the human forearm. J Physiol (1984) 2.05

Relationship between plasma propranolol concentration and relief of essential tremor. J Neurol Neurosurg Psychiatry (1979) 2.04

Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04

Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03

Modulation of motor cortical excitability by electrical stimulation over the cerebellum in man. J Physiol (1991) 2.01

Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98

Motor cortex stimulation in intact man. 1. General characteristics of EMG responses in different muscles. Brain (1987) 1.98

Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet (1977) 1.96

Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet (1994) 1.95

Performance of simultaneous movements in patients with Parkinson's disease. Brain (1986) 1.95

Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. Psychopharmacologia (1975) 1.93